Legend Biotech Corporation (NASDAQ:LEGN) has been making waves in the biotechnology sector with its flagship product, ...

Legend Biotech is a commercial-stage biotech company specializing in innovative cell therapies. Click here to find out why I ...

Carvykti (ciltacabtagene autoleucel ... Both CAR-Ts have warnings on their labels related to an increase in deaths compared to standard treatment in their pivotal studies, as well as a risk ...

Legend Biotech's future growth potential extends beyond Carvykti's current indications. The company is actively pursuing label expansions and approvals for earlier lines of treatment, which could ...

The company's focus on expanding manufacturing capacity is paying off, with management projecting over $900 million in Carvykti revenue for 2024. This growth trajectory is supported by increasing ...

Additionally, the competitive landscape reveals that CARVYKTI holds a favorable position in comparison to Arcellx’s anito-cel, with comparable efficacy and durability metrics. Although anito-cel ...

(RTTNews) - Johnson & Johnson (JNJ) announced new results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI (ciltacabtagene autoleucel; cilta-cel) significantly increased ...

Piper Sandler lowered the firm’s Carvykti revenue forecast to $290M from $335M in Q4 and to $1.63B from $1.75B in 2025 as Legend Biotech (LEGN) and Johnson & Johnson (JNJ) work to build supply.

The drug has demonstrated strong efficacy and an acceptable safety profile, especially in patients who have been heavily pre-treated, where Carvykti shows a significant survival benefit.